Macrocyclization works when design and synthesis are planned together
The useful question is not simply whether cyclization can rigidify a molecule. It is whether the chosen connection preserves the intended binding geometry while creating a route that is selective, reproducible, and expandable across an analogue series.
That requires three decisions early in a program. First, the attachment points must place the linker without disrupting essential interactions. Second, the linker must reach those points without imposing excessive strain or introducing unnecessary flexibility. Third, the precursor must carry functional groups and protecting groups compatible with a realistic ring-closing reaction.
These decisions are coupled. A linker that appears ideal in a model may require an awkward precursor or a closure that competes with elimination, oligomerization, or catalyst-sensitive functionality. A synthetically convenient connection may close cleanly but lock the molecule in the wrong conformational ensemble. Macrocyclization therefore belongs in route design from the beginning, not as a late structural decoration.
Linker design is a geometry and building-block problem
Linker selection starts with exit-vector geometry. The distance and orientation between the two connection points define a limited set of plausible chain lengths and atom patterns. Shortening the linker can increase strain; lengthening it can restore the flexibility the ring was intended to remove. Heteroatoms, unsaturation, and substitution then change polarity, torsional preferences, and the chemistry available for closure.
Building-block availability matters at the same stage. A program may need bifunctional intermediates with orthogonal protection, amino-acid derivatives for lactam closure, alkene-bearing fragments for ring-closing metathesis, aryl halide and nucleophile pairs for substitution or coupling, or alkyne and azide partners for triazole formation. If each analogue requires a new protecting-group scheme or a bespoke precursor route, exploration slows before biological data can guide the design.
Increasing sp3 character through saturated, spiro, or bridged elements can alter conformation and physicochemical behavior, but it also changes stereochemical complexity and route burden. The practical design space is therefore defined by both molecular geometry and the repeatability of precursor synthesis.
Choose the ring-closing chemistry by its failure mode
Different closure reactions solve different structural problems. The most useful comparison is often the impurity and control profile each route creates.
Macrolactamization and macrolactonization
Amide and ester closures are established choices for peptide-like and oxygen-containing macrocycles. They can be performed in solution or on solid support, including cyclization-release formats in which ring closure and resin cleavage are linked. Their familiar reagents and broad precedent are advantages, but intermolecular coupling remains a central risk. High dilution, controlled addition, activation strategy, and epimerization control can dominate scale-up planning.
Nucleophilic substitution and SNAr
SN2 and SNAr closures can provide direct access to heteroatom-linked rings. SNAr is particularly useful when an activated aromatic partner and a nucleophile can be positioned for intramolecular attack. The trade-offs include functional-group compatibility, competing elimination, and the need to carry a suitably activated precursor through earlier steps.
Ring-closing metathesis
RCM is attractive because alkene-bearing precursors are modular and modern ruthenium catalysts tolerate many functional groups. The route still has to manage precursor geometry, substitution around the reacting alkenes, E/Z outcomes, oligomer formation, and residual-metal removal. A clean analytical conversion at discovery scale does not by itself establish a transferable process.
Click and palladium-catalyzed closures
Azide-alkyne cycloaddition offers a reliable bond-forming event and can be compatible with solid-phase workflows, but the resulting triazole becomes a permanent structural element. Palladium-catalyzed reactions such as Suzuki-Miyaura, Buchwald-Hartwig, Sonogashira, Heck, and related closures provide access to biaryl, C-N, alkene, and alkyne-linked macrocycles. Catalyst selection, precursor stability, side reactions, and metal clearance must be considered together.
Biocatalysis and multicomponent reactions
Biocatalytic routes can distribute a complex synthesis across selective enzymatic steps. The enlicitide manufacturing paper demonstrates this at process level by integrating biocatalytic operations into macrocyclic peptide manufacture. Multicomponent approaches such as Ugi- or Passerini-type chemistry offer a different form of convergence, but analogue scope depends on reliable access to compatible bifunctional partners, including isonitrile building blocks.
Case studies show why the ring and route cannot be separated
Recent kinase-inhibitor programs illustrate several uses of macrocyclization. Work on WEE1 inhibitors explored macrocyclic designs in the context of adavosertib-derived medicinal chemistry. A HIPK4 program used macrocyclization of the broad-spectrum inhibitor bosutinib to reach AZ137, showing how a known scaffold can be redirected through linker and substitution-pattern design. Merck researchers applied macrocyclization to aminoquinazoline-based LRRK2 inhibitors while optimizing selectivity and central nervous system exposure.
These examples do not establish a universal advantage for macrocycles. They show that a ring can be used to test a specific hypothesis: constrain an active conformation, redirect selectivity, or alter a property profile without discarding the core binding motif. The route must then support enough analogue diversity to determine whether that hypothesis is correct.
The enlicitide case adds the manufacturing perspective. Its biocatalytic cascade is important because it treats macrocyclization as one operation within a coordinated process. That is a better model for development than optimizing closure yield in isolation while leaving upstream precursor quality and downstream purification unresolved.
What route teams should define before analogue expansion
A practical macrocycle plan should define the ring-forming atoms, expected conformational bias, precursor concentration range, protecting-group sequence, and likely intermolecular by-products. It should also identify whether the route can distinguish and control geometric isomers, oligomers, epimers, unreacted linear precursor, catalyst-derived impurities, and closely related cyclic species.
Raw-material planning should follow the same logic. Linker variants, orthogonally protected bifunctional intermediates, non-natural amino acids, alkene or alkyne handles, activated aromatic partners, and isonitrile components may all become rate-limiting inputs. Establishing identity, stereochemistry, and impurity expectations for those building blocks early makes the medicinal-chemistry cycle faster and gives process teams a clearer starting point.
Macrocyclization succeeds when molecular design, building-block strategy, reaction selection, purification, and analytics are treated as one system. The ring may create the opportunity, but route discipline determines whether the chemistry can support a program.
Frequently asked questions
What is the main scale-up risk in macrocyclization?
The intended intramolecular closure competes with intermolecular reactions that form dimers or oligomers. Concentration, addition profile, precursor conformation, and activation method all influence that balance.
When is ring-closing metathesis a useful choice?
RCM is useful when alkene-bearing precursors are accessible and the resulting unsaturation is acceptable. Route assessment should include E/Z control, catalyst loading, oligomer formation, and residual-ruthenium removal.
Why does linker availability matter so early?
The linker determines geometry and closure chemistry, while its precursor route determines how quickly analogues can be made. Limited access to bifunctional or orthogonally protected variants can narrow the design space before testing begins.
What does biocatalysis change in macrocycle manufacture?
Biocatalysis can assign different bond-forming or functional-group operations to selective enzymes. Its value is process integration: enzyme performance, substrate quality, workup, and downstream purification must be designed as a coordinated sequence.
References
- Joel L. Syphers et al., “Selective Macrocyclic WEE1 Kinase Inhibitors with Strong Efficacy against Patient-Derived Colorectal Cancer Organoids,” Journal of Medicinal Chemistry, 2026. https://doi.org/10.1021/acs.jmedchem.6c00018
- Athina Zerva et al., “Macrocyclization of Broad-Spectrum Kinase Inhibitor Bosutinib Leads to Potent and Selective Quinoline-Based HIPK4 Inhibitor AZ137,” Journal of Medicinal Chemistry, 2026. https://doi.org/10.1021/acs.jmedchem.6c01320
- Diego Garcia Jimenez et al., “Macrocycles in Drug Discovery—Learning from the Past for the Future,” Journal of Medicinal Chemistry, 2023. https://doi.org/10.1021/acs.jmedchem.3c00134
- Elsie C. Yu et al., “Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson’s Disease,” Journal of Medicinal Chemistry, 2026. https://doi.org/10.1021/acs.jmedchem.6c00238
- Artis Klapars et al., “Biocatalytic Cascades Enable Manufacture of the Macrocyclic Peptide Enlicitide,” Science, 2026. https://doi.org/10.1126/science.aed8713